Q1 estimates & analyst revisions ahead of/post Apr 28 earnings
Key Questions
What were the key highlights from Intuitive Surgical's Q4 2025 earnings?
Intuitive Surgical beat Q4 2025 EPS estimates at $2.53 with $2.87B in revenue, up 18.8-19% YoY, and margins at 37% despite tariffs. Procedures grew 19% YoY with 303 da Vinci 5 placements. FY26 guidance projects 13-15% procedure growth.
What are the expected results for Intuitive Surgical's Q1 2026 earnings?
Q1 2026 previews estimate EPS at $1.63 (+15.6%) and revenue at $2.67B (+15%), with FY26 EPS at $8.25 (+14.3%). Consensus expects EPS of $2.16, Zacks at $2.08, and revenue at $2.61B. Earnings are scheduled for April 28, 2026.
What is the analyst consensus and price targets for Intuitive Surgical?
Analysts maintain a Moderate Buy rating with price targets around $615-622, averaging $620. Simply Wall St views it as overvalued at 23% above fair value with a P/E of 56x vs. industry 27x. Bullish Citi targets $590, while Evercore ISI cut to $480.
What was Intuitive Surgical's stock price recently, and how has it performed?
As of April 7, 2026, the stock closed at $452.95, down 0.67% or $3.01, with a daily range of $447.77-$453.40. It has lagged monthly by -7.8% and is considered oversold after post-Q4 selloff.
What challenges is Intuitive Surgical facing in China?
China and OUS markets show squeezes with tenders favoring locals like MicroPort. Recent developments highlight Intuitive Surgical confronting competitive pressures in the Chinese medical device market.
What positive developments are anticipated in Japan for Intuitive Surgical?
Japan's MOH is set to finalize new guidelines in June for additional robotic procedures, providing a tailwind. This is expected to support growth amid Q1 2026 tests.
How have institutional investors been acting on Intuitive Surgical stock?
Institutional activity is mixed, with buys from Rakuten and Assenagon, but trims by others. Recent moves include Buffalo Business acquiring 2,407 shares and Quintet Private Bank selling 12,513 shares.
What factors should investors watch around Intuitive Surgical's Q1 earnings?
Key watches include guidance, deceleration risks, reserves, China/bariatrics/Japan/tariffs updates, competitor moves from MDT/JNJ, flows, and AI valuation tests. Post-Q4 selloff has shares at lows, testing valuations.
Q4 2025 beat EPS $2.53/$2.87B rev (+18.8-19%, margins 37% tariffs held ex-7c6d22e8/ex-c128f46b), procedures +19% YoY/dv5 303 placements, China OUS squeeze tenders favor locals/MicroPort ex-1A8yhTcx/ex-56158c28/ex-3a0354c1 YT; FY26 guide 13-15% proc growth; Japan MOH guidelines June tailwind ex-c3346fb7. Q1 preview ex-fdac8224: EPS $1.63 (+15.6%)/$2.67B (+15%), FY26 $8.25 (+14.3%); consensus EPS $2.16/Zacks $2.08/$2.61B/Moderate Buy $615-622/$620 PT/Simply Wall St $611 bull DCF $369 overvalued/23% above fair value P/E 56x vs 27x ind ex-1ADIgK2j/33d516ff/1AE4bjbD/2a14fd84 stable ex-81991da2/ex-4c76c208 (-7.8% monthly lag, 2026-04-07 $452.95 ex-48a89eda); AAII F; Evercore ISI $480 cut/analyst $603 ex-1ADxifEV; bull Citi $590/Motley Fool monopoly ex-52aa7c87; institutional mixed (Rakuten/Assenagon vs trims ex-64cdd355/cc592912/ex-6fe7070a)/ex-cc24e152/ex-15fbe704; $453 low oversold/post-Q4 selloff ex-c128f46b/bearish ex-73ffea62/ex-f566abd2. Watch guidance/decel/reserves/China/bariatrics/Japan/tariffs/MDT-JNJ/flows/AI valuation test ex-2a14fd84.